43 results about "Streptococcus pneumoniae conjugated" patented technology

The invention provides Fe3O4 (at) Au-WGA nanoparticles, a preparation method thereof, an SERS tag and a detection product, and particularly relates to the technical field of nano materials. The Fe3O4 (at) Au-WGA nano particle sequentially comprises a Fe3O4 inner core, a polymer layer, a nano Au layer, a first Raman molecular layer, an Au shell layer, a second Raman molecular layer and a WGA molecular layer from inside to outside, and has relatively strong paramagnetism, a stable structure and monodispersity. The two Raman molecular layers can generate stable and strong SERS signals, the outer Raman molecular layer is connected with WGA molecules, and influenza A virus and streptococcus pneumoniae can be captured at the same time. The invention further aims to provide an SERS label and a detection product based on the Fe3O4 (at) Au-WGA nano particle, so as to improve a detection method and a detection product based on a Raman spectrum.

The present application belongs to the technical field of biological medicine, and particularly relates to a thiol phenylboronic acid mediated nano-enzyme immunochromatography reagent and application thereof. The present application utilizes the broad-spectrum binding ability of MPBA to the glycosylated molecules on the surface of pathogens, and combines the colorimetric catalytic double enhancement effect of the virus-like biomimetic magnetic nano-enzyme (FeAu@AuIr), to improve the detection sensitivity. The probe takes Fe3O4 magnetic nanoparticles as the core, and sequentially loads large-diameter gold nanoparticles (Au) and gold-iridium alloy (AuIr) with high catalytic activity, to enhance the pathogen capture capacity and signal amplification effect. Combined with the antibody modified immunochromatography strip, Streptococcus pneumoniae, Pseudomonas aeruginosa and SARS-CoV-2 can be simultaneously detected, and the detection sensitivity is greatly improved. Through verification of 170 clinical samples, the present application has good application prospect in on-site rapid detection, and provides an efficient and low-cost solution for precise screening of respiratory tract infectious pathogens.

The application discloses a digital image quantitative dual-mode detection system and method based on a cascade enhanced nano-enzyme, which comprises a probe prepared from a membrane nano-enzyme material, an immunochromatography test strip and a signal automatic analysis system, the nano-enzyme material takes molybdenum disulfide nanosheets as a substrate, sequentially loads large-diameter platinum-iridium alloy particles and small-diameter platinum-iridium alloy particles through polyethylene imine-mediated electrostatic self-assembly, and forms a high-density catalytic active site array. The probe is coupled with specific antibodies on the surface of the nano-enzyme material. Based on the inherent light absorption and peroxidase-like activity of the probe, a dual-mode detection strategy of physical color development-catalytic enhancement is established, high-concentration sample visual preliminary screening and low-concentration sample ultra-sensitive quantitative detection are realized, and combined with an adaptive cross-peak colorimetric quantitative algorithm, individual visual perception differences can be effectively eliminated, and on-site rapid quantitative screening of community-acquired pneumonia pathogens such as streptococcus pneumoniae and legionella pneumophila can be realized.

The application discloses a freeze-drying protective agent for Streptococcus pneumoniae without animal source, and belongs to the field of microorganism preservation. The freeze-drying protective agent is composed of the following components: 1-5% (weight / volume) soybean peptone, 1-5% (weight / volume) trehalose, 4-8% (weight / volume) mannitol and 0.3-1.5% (volume / volume) glycerol, and the rest is water. The freeze-drying protective agent can better maintain the activity of Streptococcus pneumoniae, and the effect is equivalent to that of a skimmed milk protective agent or a commercially available freeze-drying protective agent without animal source, but the freeze-drying protective agent does not contain animal source components and has low cost.

The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.

The present disclosure relates to pharmaceutical compositions comprising live bacteria strains, and / or bacteriocin molecules which can inhibit the growth and persistence of a pathogen such as S. pneumoniae. Further aspects of the present disclosure relate to the use of the pharmaceutical populations for preventing or treating disease caused by S. pneumoniae, or use of compositions comprising live bacteria as probiotics.

The present application relates to the technical field of biology, in particular to a streptococcus pneumoniae urine antigen ELISA kit and a preparation method thereof.The solid-phase coating material of the kit is CRP, which is easy to prepare and obtain and low in cost;the reaction system only needs one antibody, greatly reducing the workload and labor cost of screening and preparation of paired antibodies;the antigen detection is fully automatic, greatly increasing the detection throughput and reducing the labor cost.

The present invention relates to a multiplex gene detection system for viral and bacterial infection of the central nervous system, comprising forward and reverse primers for detecting enterovirus, human double echovirus, Mycobacterium tuberculosis, Listeria monocytogenes, Streptococcus pneumoniae, varicella zoster virus, mumps virus, cytomegalovirus, herpes simplex virus type 1, herpes simplex virus type 2, Neisseria meningitidis, Epstein-Barr virus, Streptococcus agalactiae, Haemophilus influenzae, human herpes virus type 6, Escherichia coli K1 and Japanese encephalitis virus, and the detection sample is cerebrospinal fluid. The multiplex gene detection product for viral and bacterial infection of the central nervous system of the present invention has high throughput, low cost, high sensitivity and good specificity, and is used for synchronous identification and semi-quantitative analysis of multiple viral and bacterial infections of the central nervous system.

The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate), and to the use thereof. The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate). The vaccine formulations of the present invention would typically include at least one glycoconjugate from Streptococcus pneumoniae serotype in a formulation designed to promote resuspension.

To provide additional pneumococcal vaccine compositions which can provide protection against pneumococcal serotypes not present in currently available vaccines.SOLUTION: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, where each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein. In some embodiments, at least one polysaccharide protein conjugate is formed by a conjugation reaction comprising an aprotic solvent. In other embodiment, each of the polysaccharide protein conjugates are formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient.SELECTED DRAWING: Figure 1

The invention discloses an application of adenosine in preparing or preventing a chronic obstructive pulmonary disease, the chronic obstructive pulmonary disease refers to an acute exacerbation stage of the chronic obstructive pulmonary disease, and the acute exacerbation stage of the chronic obstructive pulmonary disease is caused by streptococcus pneumoniae; the medicine is used for inhibiting cell activation and proinflammatory factor release through an A2AR receptor. The invention provides a powerful scientific basis for application of adenosine in preparation of related drugs in treatment and prevention of lung diseases, especially chronic obstructive pulmonary diseases.

The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Streptococcus pneumoniae.

The present invention is directed to complexes comprising multivalent compounds, immunogenic compositions, and vaccines comprising carrier protein coupled to pegylated bacterial capsular polysaccharides and uses thereof. In particular, compositions of the invention comprise bacterial capsular conjugated to polyethylene glycol (PEG) and like compounds to which are couple linkers and / or carrier proteins. PEGylated polysaccharides are derived from many different bacterial serotypes such as Streptococcus pneumoniae. The carrier protein may be coupled to the pegylated polysaccharide through homo or hetero mono-functional, bi-functional, and / or multi-functional linkers.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), and uses of the novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates). The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes that are not found in Prevnar, Synflorix and / or Prevnar 13. The invention also relates to vaccination of human individuals, particularly infants and elderly people, against Streptococcus pneumoniae infection using the novel immunogenic compositions.

The invention discloses a method for quantitatively analyzing the content of alpha2-3 acetylneuraminic acid in glycoprotein, which comprises the following steps: firstly, treating a sample containing glycoprotein by using streptococcus pneumoniae acetylneuraminidase, and continuously treating the sample containing glycoprotein by using clostridium perfringens acetylneuraminidase in the same solution; centrifugally separating and taking a separating solution containing two acetylneuraminic acid products outside the centrifugal tube; and detecting and collecting two hydrolysates 2, 7-dehydrated acetylneuraminic acid and the signal intensity of acetylneuraminic acid in a negative ion mode, and calculating the percentage content of alpha2-3 linked acetylneuraminic acid by using a formula. According to the method, the sensitivity of quantitative analysis of alpha2-3 acetylneuraminic acid can be improved, and the time consumption of detection and analysis is reduced.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising such immunogenic compositions and uses thereof. The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes that are not present and / or in. The invention also relates to vaccination of human individuals, especially infants and elderly people, against Streptococcus pneumoniae infection using such novel immunogenic compositions.

To provide a method for preparing a polysaccharide-protein conjugate.SOLUTION: A method for preparing a pneumococcal serotype 3 polysaccharide-CRM197 carrier protein conjugate by reductive amination includes: a) allowing pneumococcal serotype 3 polysaccharide to react with oxidizer to form activated pneumococcal serotype 3 polysaccharide; and b) allowing the activated pneumococcal serotype 3 polysaccharide to react with CRM197 carrier protein in aprotic solvent to form a pneumococcal serotype 3 polysaccharide-CRM197 carrier protein conjugate. The obtained conjugate has higher antigenicity measured by an opsonin phagocytic extinction assay and an electrochemiluminescence immunogenic assay compared to the pneumococcal serotype 3 polysaccharide-CRM197 carrier protein conjugate prepared according to the processes a) and b) in which the activated pneumococcal serotype 3 polysaccharide is allowed to react with CRM197 carrier protein in aqueous solution.SELECTED DRAWING: Figure 1

The invention discloses a streptococcus pneumoniae PsaA protective epitope peptide, a vaccine and a preparation method and application thereof, the nucleotide sequence of the epitope peptide is shown as SEQ ID NO.1, a novel epitope vaccine ZnuA-PsaA-Loop90 (for short, ZPL90) is successfully constructed based on the epitope, after the vaccine is inoculated, an anti-Loop90 antibody can be efficiently induced in a mouse, the mouse can be effectively protected from being infected with streptococcus pneumoniae, and the streptococcus pneumoniae PsaA protective epitope peptide can be used for preparing the vaccine. Good application prospects are realized.

The present disclosure relates to media and fermentation methods for polysaccharide production in bacterial cell culture. In one aspect, the disclosure relates to cell culture media comprising potassium phosphate and calcium chloride. In another aspect, the disclosure relates to a method of fermenting bacterial cell culture under pressurized conditions. The media and methods disclosed herein are useful for increasing the polysaccharide production and reducing the lag phase of a bacterial cell culture, i.e., Streptococcus pneumoniae.

The present invention relates to novel inhibitors of the Energy Coupling Factor (ECF) Transporters. These compounds of general formula (Ia) or (Ib) are useful in the treatment of bacterial infections, especially caused by Streptococcus pneumoniae, Enterococcus faecium, Enterococcus faecalis.

The invention relates to the field of health care, and more particularly to the prevention of infections that cause pneumonia and other illnesses using an immunogenic protein containing fragments of the proteins FliC, PspA, OmpA and PE, connected by rigid linkers, wherein: - the FliC protein fragment contains SEQ ID NOs: 2 and 3 connected to one another by a flexible linker; - the PspA protein fragment contains SEQ ID NO: 4; the OmpA protein fragment contains SEQ ID NOs: 5-8 connected to one another by flexible linkers; - the PE fragment contains SEQ ID NO: 9. Also proposed are a host cell and a method for producing the protein. The immunogenic protein is suitable for use as a broad-spectrum polyvalent vaccine and exhibits a marked protective effect against Streptococcus pneumoniae, Haemophilus influenzae and Klebsiella pneumoniae, as well as providing for production efficiency and safety.

This invention discloses a quinolinonylpropane sulfonate, its preparation method, and its application. The structural formula of the quinolinonylpropane sulfonate is shown in formula (III). The preparation method is as follows: using 4-methylquinoline and 1,3-propanesulfonic acid lactone as raw materials, a reaction is carried out to obtain product (I); using (4-(diphenylamino)phenyl)boronic acid and 7-bromobenzo[c][1,2,5]thiadiazole-4-carboxaldehyde as raw materials, a coupling reaction is carried out under potassium carbonate and nitrogen atmosphere catalyzed by tetrakis(triphenylphosphine)palladium to obtain product (II); using products (I) and (II) as raw materials, quinolinonylpropane sulfonate (III) is prepared. The quinolinonylpropane sulfonate of this invention exhibits antibacterial activity, especially against Streptococcus pneumoniae, and can be used as an antibacterial agent.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

The invention relates to capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.

The present invention is directed to complexes comprising multivalent compounds, immunogenic compositions, and vaccines comprising carrier protein coupled to pegylated bacterial capsular polysaccharides and uses thereof. In particular, compositions of the invention comprise bacterial capsular conjugated to polyethylene glycol (PEG) and like compounds to which are couple linkers and / or carrier proteins. PEGylated polysaccharides are derived from many different bacterial serotypes such as Streptococcus pneumoniae. The carrier protein may be coupled to the pegylated polysaccharide through homo or hetero mono-functional, bi-functional, and / or multi-functional linkers.

The invention provides an intelligent processing method and device for a streptococcus pneumoniae serological response image, and relates to the field of data processing. According to the method, multispectral image data of a reaction product is obtained by using quantum dots with tunable emission characteristics in a composite reaction system, spectral components are generated through quantum Fourier transform and quantum matrix decomposition, and a spectral mode with unique spectral characteristics is obtained through quantum calculation optimization. Then, blind source separation and a deep self-encoding network are adopted to generate independent spectral components, and quantitative analysis and result optimization are completed in combination with spectral characteristics and concentration information. And finally, based on the quantitative analysis result, carrying out classification and identification, outputting the spectral mark and concentration value of each reaction product, and realizing accurate characterization of the reaction products. By implementing the technical scheme provided by the invention, the processing precision of the streptococcus pneumoniae serological response image can be improved.

The present invention belongs to the field of pharmaceutical synthesis technology, specifically relating to the synthesis and application of (4-benzyl(p-tolylthio)amino)benzenesulfonamide compounds. The (4-benzyl(p-tolylthio)amino)benzenesulfonamide compounds described herein utilize relatively inexpensive, common raw materials such as N-chlorosuccinimide, p-tolylthiophenol, dichloromethane, and triethylamine during the synthesis process. A stable intermediate, 1-(p-tolylthio)pyrrolidine-2,5-dione, is synthesized, and the target product is obtained in a high overall yield. The entire synthetic process is economical, safe, and simple. The two synthesized new (4-benzyl(p-tolylthio)amino)benzenesulfonamide compounds exhibit significant anti-Streptococcus pneumoniae activity.

Disclosed herein are compositions, methods of treatment and kits for treating Streptococcus Pneumoniae infections. In some examples, compositions including cyclic dominant negative competence stimulating peptide analogs are disclosed and used for treating Streptococcus Pneumoniae infections.

The invention relates to a double-signal nanoprobe based on silicon dioxide interlayer protection as well as a preparation method and application of the double-signal nanoprobe. The nanoprobe has a core-shell structure, and the core-shell structure comprises an inner core and an outer shell layer coating the outer surface of the inner core; the inner core is SiO2 nano particles; the outer surface of the inner core comprises an outer shell layer of the core-shell structure formed by sequentially coating a first cationic polymer interlayer, a gold nanoparticle interlayer, a SiO2 inner shell layer, a second cationic polymer interlayer and a carboxylated quantum dot outer shell layer. The invention provides a double-signal nanoprobe based on silicon dioxide interlayer protection, and the nanoprobe not only has a good colorimetric signal, but also has a strong fluorescence signal. After the nanoprobe is coupled with a streptococcus pneumoniae antibody, streptococcus pneumoniae in a sample can be selectively detected, colorimetric and fluorescence signals can be output at the same time, and rapid and high-sensitivity detection of streptococcus pneumoniae is achieved.